Precision BioSciences Inc. (DTIL) reports earnings

The report was filed on March 26, 2025

We may earn a commission from links on this page.
In This Story

Precision BioSciences Inc. (DTIL+0.85%) has submitted its 10-K filing for the fiscal year ended December 31, 2024.

The filing details Precision's focus on developing gene editing therapies using its proprietary ARCUS platform. The company is advancing programs targeting hepatitis B, Duchenne muscular dystrophy, and certain hemoglobinopathies.

Precision's lead program, PBGENE-HBV, is designed to eliminate cccDNA in hepatitis B patients. The ELIMINATE-B trial is ongoing, with initial safety evaluations showing the treatment was well tolerated.

Advertisement

The company also highlighted its PBGENE-3243 program for mitochondrial disease, which aims to eliminate mutant mitochondrial DNA. An IND application is anticipated in 2025.

Advertisement

Precision has partnerships with Novartis and iECURE for in vivo gene editing programs targeting hemoglobinopathies and ornithine transcarbamylase deficiency, respectively.

Advertisement

The company reported a net income of $7.2 million for 2024, with an accumulated deficit of $482.5 million. Precision anticipates its cash resources will fund operations into the second half of 2026.

Precision's intellectual property portfolio consists of issued patents and pending applications related to its ARCUS platform and in vivo gene editing technologies.

Advertisement

The company faces risks including competition in the gene editing field, potential delays in clinical trials, and the need for substantial additional funding.

Precision is also subject to various regulatory requirements and potential changes in healthcare laws that could impact its operations and financial condition.

Advertisement

The company does not currently intend to pay dividends, focusing instead on reinvesting in research and development activities.

This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the Precision BioSciences Inc. annual 10-K report dated March 26, 2025. To report an error, please email earnings@qz.com.